Search Results

Earlier this year, scientists from Columbia University in New York demonstrated that the growth rate of pancreatic cancer, measured in patients’ blood using CA19-9 as biomarker, determines survival chances and can be used as a quick way to assess treatment effectiveness.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

The University of Cincinnati Cancer Center inaugurated its state-of-the-art Blood Cancer Healing Center, revolutionizing blood cancer care in the United States.

ProSomnus, Inc. today announced full enrollment in the First Line Obstructive Sleep Apnea Treatment study (FLOSAT). FLOSAT is a prospective, independent, head-to-head, crossover study comparing the effectiveness of precision oral appliance therapy (OAT) as first-line treatment versus continuous positive airway pressure (CPAP) therapy.

NORTH CHICAGO, ILLINOIS, May 15, 2024 — Rosalind Franklin University’s Helix 51 biomedical incubator, the only one of its kind in Lake County, Illinois, celebrated its fifth year of...

Molecular Targeting Technologies, Inc. (MTTI) and University of Antwerp today announced the approval of a Clinical Trial Application by the European Federal Agency for Medicines and Health Products (FAMHP) (equivalent to a US IND). The clinical study will evaluate the safety, dosimetry and treatment response of TDURA ( 99m Tc-Duramycin), in patients with advanced colorectal cancer (CRC)*.